Allergan builds NASH business through $50mm Akarna buy
Continuing with its September buying spree, Allergan PLC announced that it is paying $50mm in cash to acquire Akarna Therapeutics Ltd., a two-year-old firm developing small-molecule therapies for fibrotic and inflammatory diseases.
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash for Equity
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com